SCHEMBL2579112

SCHEMBL2579112

OC(c1ccc(OC(F)(F)F)cc1)c1ccccc1OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
TOP2A P11388 1/20 0.45
TOP2B Q02880 1/20 0.45
MAPT P10636 1/20 0.44
MRGPRX4 Q96LA9 2/20 0.44
SCD O00767 1/20 0.42
DRD2 P14416 1/20 0.41
DRD1 P21728 1/20 0.41
LMNA P02545 3/20 0.41
GAA P10253 2/20 0.41
HPGD P15428 1/20 0.41
CASP3 P42574 1/20 0.41
HTT P42858 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
GRIN2B Q13224 1/20 0.40
ALDH1A1 P00352 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14033550 0.85 TOP2A (0.47) TOP2ATOP2BDRD2DRD1GRIN2B
SCHEMBL2579107 0.85 RXRA (0.55) RXRARXRBRXRGMAPTDRD2
SCHEMBL2579113 0.84 PPIA (0.46) RXRARXRBRXRGTOP2ATOP2B
SCHEMBL31041187 0.84 SLC6A9 (0.47) MAPTDRD2DRD1LMNAHPGD
SCHEMBL477534 0.83 DRD2 (0.55) MAPTDRD2DRD1LMNAALDH1A1
SCHEMBL1539311 0.81 LIPE (0.45) RXRARXRBRXRGMAPTMRGPRX4
SCHEMBL2578523 0.80 SGMS2 (0.54) RXRARXRBRXRGMAPTDRD2
SCHEMBL2577406 0.80 LIPE (0.46) RXRARXRBMAPTMRGPRX4DRD2
SCHEMBL2575133 0.80 DRD2 (0.46) MAPTDRD2DRD1LMNAHTT
SCHEMBL2577640 0.80 SGMS2 (0.54) RXRARXRBMAPTDRD2DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048897-B2 Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-01 US disclosed
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-12-25 US disclosed
EP-1783110-A1 NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes SLC5A1, GPR119, SLC5A2 RXRA 1228/4885RXRB 1465/4885RXRG 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.